Preclinical evaluation of the PARP inhibitor BMN-673 for the treatment of ovarian clear cell cancer
Paul M Wilkerson(Institute of Cancer Research), Jorge S. Reis‐Filho(Memorial Sloan Kettering Cancer Center)
Cited by 15
Related Papers
Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas
|Nature Communications|2018|138